View Older Stories View More Recent Stories

Mar 14, 2022 04:05PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 2, 2022 05:30AM Arcutis to Present at Upcoming Investor Conference
Mar 2, 2022 05:30AM Arcutis to Present at Upcoming Investor Conference
Feb 22, 2022 04:01PM Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 22, 2022 04:01PM Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 1, 2022 08:00AM Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Feb 1, 2022 08:00AM Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Dec 23, 2021 08:00AM Arcutis Biotherapeutics (ARQT) Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
Dec 23, 2021 08:00AM Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
Dec 23, 2021 08:00AM Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
Dec 22, 2021 04:02PM Arcutis Biotherapeutics Inc. (ARQT) Announces FDA Accepts NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Dec 22, 2021 04:01PM FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Dec 22, 2021 04:01PM FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Dec 16, 2021 08:00AM Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary
Dec 16, 2021 08:00AM Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary
Dec 13, 2021 08:00AM Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
Dec 13, 2021 08:00AM Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
Nov 10, 2021 08:02AM Arcutis to Present at Upcoming Investor Conference
Nov 10, 2021 08:02AM Arcutis to Present at Upcoming Investor Conference
Nov 4, 2021 04:02PM Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 4, 2021 04:02PM Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
Oct 4, 2021 08:01AM Arcutis Biotherapeutics (ARQT) Submits Topical Roflumilast Cream NDA to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
Oct 4, 2021 08:00AM Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
Oct 4, 2021 08:00AM Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
Sep 30, 2021 08:40AM Arcutis Biotherapeutics (ARQT) Announces New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at EADV
Sep 30, 2021 08:30AM New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
Sep 30, 2021 08:30AM New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
Sep 28, 2021 04:09PM Arcutis Biotherapeutics Inc. (ARQT) Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
Sep 28, 2021 04:05PM Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
Sep 28, 2021 04:05PM Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
Sep 27, 2021 08:05AM New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
Sep 27, 2021 08:05AM New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
Sep 9, 2021 04:10PM Arcutis to Present at Upcoming Investor Conferences
Sep 9, 2021 04:10PM Arcutis to Present at Upcoming Investor Conferences
Sep 2, 2021 04:11PM Arcutis Biotherapeutics Inc. (ARQT) Appoints Keith Leonard to its Board
Sep 2, 2021 04:10PM Arcutis Announces Appointment of Keith Leonard to Board of Directors
Sep 2, 2021 04:10PM Arcutis Announces Appointment of Keith Leonard to Board of Directors
Aug 25, 2021 08:00AM Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Aug 25, 2021 08:00AM Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Aug 23, 2021 08:00AM Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
Aug 5, 2021 04:05PM Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
Aug 5, 2021 04:05PM Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
Aug 2, 2021 04:05PM Arcutis Announces Additions to its Investor Relations and Communications Team
Aug 2, 2021 04:05PM Arcutis Announces Additions to its Investor Relations and Communications Team
Jul 21, 2021 08:00AM Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
Jul 21, 2021 08:00AM Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
Jul 12, 2021 08:00AM Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Jul 12, 2021 08:00AM Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Jul 1, 2021 06:00AM Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
Jul 1, 2021 06:00AM Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
View More Recent Stories View Older Stories